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http://dx.doi.org/10.1016/j.ccell.2014.11.014SUMMARYBrafV600E induces benign, growth-arrested melanocytic nevus development, but also drives melanoma
formation. Cdkn2a loss in BrafV600E melanocytes in mice results in rare progression to melanoma, but only
after stable growth arrest as nevi. Immediate progression to melanoma is prevented by upregulation of
miR-99/100, which downregulates mTOR and IGF1R signaling. mTORC1 activation through Stk11 (Lkb1)
loss abrogates growth arrest of BrafV600E melanocytic nevi, but is insufficient for complete progression to
melanoma. Cdkn2a loss is associated with mTORC2 and Akt activation in human and murine melanocytic
neoplasms. Simultaneous Cdkn2a and Lkb1 inactivation in BrafV600E melanocytes results in activation of
both mTORC1 and mTORC2/Akt, inducing rapid melanoma formation in mice. In this model, activation of
both mTORC1/2 is required for Braf-induced melanomagenesis.INTRODUCTION
Benign lesions with the potential to give rise to malignancy exist
in many different tissue types. The characteristics of theseSignificance
Certain oncogenes such as BrafV600E induce oncogene-induce
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mTORC1 Regulates BrafV600E-Induced Growth Arrest(MAPK) pathway activation, often through activating mutations
to amember of RAS or RAF oncogenes. The process of transient
proliferation but ultimate growth arrest is thought to be due to a
process termed oncogene-induced senescence (OIS). Mecha-
nisms enforcing OIS have largely been defined using in vitro
models and include induction of p53 and/or the DNA damage
response, upregulation of cyclin-dependent kinase inhibitors
(CKIs), or upregulation of secreted factors (Kuilman et al.,
2010). Commonly used markers for OIS include senescence-
associated b-galactosidase (SA-b-gal) staining, increased
p16Ink4a staining, and a large and flattened cell morphology (Kuil-
man et al., 2010).
Acquired melanocytic nevi are composed of growth-arrested
melanocytes. About 80% of nevi have BRAFV600E mutations
(Pollock et al., 2003). In nevi, like other precursor lesions, OIS
is thought to prevent full malignant transformation. However,
the observation that approximately 33% of melanomas originate
from benign nevi (Gruber et al., 1989; Tsao et al., 2003) and that
BRAFV600Emutations are also found in about 50%ofmelanomas
(Tsao et al., 2012), suggest that, under appropriate conditions,
OIS can be bypassed. CDKN2A, a familial melanoma locus, en-
codes two tumor suppressors, p16Ink4a and p14Arf, both of which
are thought to restrict melanoma formation. Both tumor suppres-
sors have been previously implicated in OIS, but may not be
absolutely required for this process (Dhomen et al., 2009; Hafer-
kamp et al., 2009).
Analyses of human melanocytic lesions have been difficult to
interpret in the context of current OIS models. For example, pre-
dicted stainingpatternsof proposedmediators and/ormarkers of
OIS are inconsistent with observed staining patterns in human
melanocytic lesions and are unable to reproducibly distinguish
between benign melanocytic nevi and malignant melanoma
(Tran et al., 2012). Further, current models for OIS based on
in vitro work do not account for variable clinical phenotypes in
human melanocytic nevi, such as the following: (1) variable and
often large size of benign lesions, (2) low but positive basal Ki67
staining in nevi, (3) differences in cytology within the same nevus,
and (4) partial regrowth of melanocytic nevi following incomplete
removal (recurrent nevus phenomenon). Current OIS models do
not explain the following: (1) how many rounds of replication
can occur prior to growth arrest, (2) whether bypass of OIS is suf-
ficient for malignant transformation, and (3) how resumption of
growth as part of transformation to melanoma is possible.
Expression of BrafV600E in mouse melanocytes results in the
formation of benign melanocytic proliferations akin to human
nevi (Dankort et al., 2009; Dhomen et al., 2009; Goel et al.,
2009). Mouse models have shown that constitutive activation
of PI3K/Akt signaling through loss of Pten relieves OIS induced
by Ras/Raf mutations in vivo (Dankort et al., 2009; Kennedy
et al., 2011; Vredeveld et al., 2012), an observation consistent
with analyses of human melanocytic lesions (Vredeveld et al.,
2012). These observations suggest that downstream substrates
of activated PI3K/Akt signaling are critical in mediating bypass of
OIS, though, as such pathway substrates are numerous, the
critical factors regulating this effect are unknown.
In this study, mouse models based on melanocyte-specific
BrafV600E mutation were generated with the objective of better
understanding the dynamics of—and factors regulating—pre-
cursor lesion formation and natural history in vivo.42 Cancer Cell 27, 41–56, January 12, 2015 ª2015 Elsevier Inc.RESULTS
BrafV600E Mutation and Cdkn2a Inactivation Lead to
Formation of Growth-Arrested Melanocytic Nevi
Mice carrying Tyrosinase::CreERT2 (TC) and BrafCA alleles (Dan-
kort et al., 2009) were crossed with Cdkn2alox mice (Aguirre
et al., 2003). In the resulting TC;Cdkn2alox/lox;BrafCA/WT mice
(Cdkn2a/Braf), induction of recombinationwith topical 4-hydroxy-
tamoxifen (4-HT) resulted in simultaneous BrafV600Emutation and
Cdkn2a inactivation, specifically in melanocytes. Melanocytic
proliferation inCdkn2a/Brafmiceensuedwithindays in thehair fol-
licle bulb withmelanocytes subsequently spreading into the adja-
cent dermis by postnatal days 14–17 (Figures 1A and 1B and
Figure S1A available online). Transient proliferation after Braf acti-
vation was confirmed with Ki67 staining (Figures S1B and 1C).
Clinically apparent growth arrest of these lesions was evident by
day 28 (Figures 1A and 1D), after which nevi remained stable in
size throughout the lifetime of themouse (Figures 1A, 1E, and 1F).
Cdkn2a/Braf nevi stained positively for the melanocyte marker
S100 (Figure S1C). All immunohistochemistry (IHC) and fluores-
cence microscopy was performed in genotype-matched albino
mice, in which melanocyte proliferation phenotypes were repro-
duced but without melanin pigment production (which can
impair interpretation of IHC data). Cdkn2a/Braf nevi did not
show mitotic figures (Figure S1D); had low Ki67 indices (Figures
1C and S1B); did not show features of apoptosis, such as py-
knotic nuclei or cleaved caspase 3 staining (Figure S1E; data
not shown); and were negative for g-H2AX (Figure S1E), which
can indicate a DNA damage response when present. These
characteristics are consistent with observations in human nevi,
which have low Ki67 indices (Soyer et al., 1989) despite stability
in size over time, relatively low g-H2AX staining (Tran et al.,
2012), and rare apoptosis (Woenckhaus et al., 2003).
Interestingly, Cdkn2a/Braf nevi were approximately three
times larger and more numerous than nevi induced by BrafV600E
alone (Dankort et al., 2009; Figures S1F and S1G), suggesting
that Cdkn2a loss may temporarily disrupt, but not abrogate
OIS. These data are consistent with the observation that patients
with germlineCDKN2Amutations also have larger andmore nevi
(Florell et al., 2004).
Growth-Arrested Melanocytic Nevi Stochastically
Progress to Melanoma at Rates Similar to Human Nevi
Mice bearing Cdkn2a/Braf melanocytic nevi develop melanoma
with 100% penetrance as they age (Figures 2A and 2B). As a sig-
nificant proportion of human melanomas develop from preexist-
ing melanocytic nevi, the possibility that melanoma formation in
Cdkn2a/Braf mice resulted from rare, stochastic reactivation of
growth in individual nevi was considered. In humans, malignant
progression of a nevus is demonstrated by histologic continuity
of a nevus with a melanoma (Gruber et al., 1989; Tsao et al.,
2003), a finding supported by the genetic similarity of such paired
nevi and melanomas (Dadzie et al., 2009). Upon histologic anal-
ysis, Cdkn2a/Brafmelanomas showed histologic contiguity with
preexisting nevi (Figure 2C), supporting the hypothesis that
melanoma formation in this model is associated with malignant
progression of nevi.
Cdkn2a/Braf tumors stained positively for S100 (Figure 2D).
In contrast to growth-arrested nevi, Cdkn2a/Braf tumors were
Figure 1. BrafV600E Mutation and Cdkn2a Inactivation Lead to Formation of Growth-Arrested Melanocytic Nevi
(A) Stereomicroscopy of flank skin on postnatal days 14, 28, and 90 inCdkn2a andCdkn2a/Brafmice. Arrowhead indicates melanocyte escape from hair follicles
prior to nevus formation. Day 14 corresponds to a pregrowth-arrest time point, and days 28 and 90 correspond to growth-arrested time points; scale bars, black,
300 mm; white, 25 mm; red, 1.2 mm; and yellow, 150 mm.
(B) Hematoxylin and eosin (H&E)-stained flank skin from a 14-day-old Cdkn2a/Braf mouse. Arrowhead shows melanocytes just prior to (black) and just after
(white) escape from the hair follicle into the dermis; scale bar, 20 mm.
(C) Ki67 indices ofCdkn2a/Braf lesions at different time points and Trp53/Braf melanocytic nevi. Error bars represent SEM. NS indicates no statistically significant
difference.
(D) H&E-stained flank skin from a 28-day-old Cdkn2a/Braf mouse. Boxes show individual nevi; scale bar, 40 mm.
(E) H&E-stained flank skin from a 90-day-old Cdkn2a/Braf mouse. Boxes show individual nevi; scale bar, 40 mm.
(F) Quantification of melanocytes per square millimeters in Braf and Cdkn2a/Braf mice. Error bars represent SEM. NS indicates not significant.
See also Figure S1.
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Figure 2. Growth-Arrested Melanocytic
Nevi Stochastically Progress to Melanoma
at Rates Similar to Human Nevi
(A) Kaplan-Meier survival curve of mice treated
perinatally with 4-HT.
(B) Melanoma in an adult Cdkn2a/Braf mouse.
(C) Cdkn2a/Braf nevi in association with mela-
noma; the outlined region is shown at a higher
power (right). Black and white arrowheads indicate
nevus cells and melanoma cells, respectively;
scale bars, black, 500 mm; and yellow, 50 mm.
(D) S100 IHC of a Cdkn2a/Braf melanoma; scale
bar, 250 mm.
(E) A Cdkn2a/Braf melanoma at high power; scale
bar, 20 mm.
See also Figure S2.
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mTORC1 Regulates BrafV600E-Induced Growth Arrestcomposed of large, pleomorphic cells with prominent nucleoli
and had high Ki67 indices (Figures 1C and 2E). PCR confirmed
recombination of both Cdkn2alox and BrafCA alleles in these
melanomas (Figures S2A and S2B). Micrometastases to lymph
nodes were noted, however systemic metastases were not
observed (data not shown).
The p53 signaling and DNA damage response pathways are
thought to play an important role in OIS (Kuilman et al., 2010).
Although a p53-deficient background appears to accelerate
BRAFV600E-induced melanomagenesis in vivo (Goel et al.,
2009), the specific effect of p53 loss in individual melanocytic
lesions is unclear. To address this, TC;BrafCA mice were mated
to mice with a conditionally inactivatable Trp53lox allele (Jonkers
et al., 2001). Despite inactivation of p53, melanocytic nevi still
exhibited a growth-arrest phenotype that was similar to the
Cdkn2a/Braf model (Figures 1C, S2C, and S2D) and stochasti-
cally progressed to melanoma with a similar latency and
frequency as Cdkn2a/Braf mice (Figures S2E–S2G). Trp53/Braf
tumors had more pronounced cytological atypia and pleomor-
phism than Cdkn2a/Braf melanomas (Figure S2H). The similar-
ities in nevus formation and progression kinetics were striking
and suggested that similar processes may be enforcing growth
arrest in both the Cdkn2a/Braf and Trp53/Braf models.
The rate of nevus progression to melanoma in humans has
been estimated to be approximately 1/16,000 by the age of
50 (Tsao et al., 2003). A roughly similar progression rate of 1/
17,600 was estimated in the Cdkn2a/Braf model (see Supple-
mental Experimental Procedures), suggesting that mechanisms44 Cancer Cell 27, 41–56, January 12, 2015 ª2015 Elsevier Inc.regulating growth arrest and progression
may be similar between the Cdkn2a/Braf
model and humans. The Cdkn2a/Braf
model exhibits defined and reproducible
progression kinetics, allowing for evalua-
tion of factors regulating growth arrest
and progression to malignancy in vivo
(Figure S2I).
Melanocytic Nevi and Melanomas
Differ in mTORC1 Pathway
Activation Status
To better understand factors regulating
both growth arrest and progression ofnevi to melanoma, Cdkn2a/Braf mice were mated to iDct-GFP
mice (Zaidi et al., 2011). Uncultured, GFP+ melanocytes were
purified by fluorescence-activated cell sorting (FACS) at pre-
growth arrest (postnatal day 17) and growth-arrested (postnatal
day 50) time points for global mRNA expression analysis. Fluo-
rescence microscopy and GFP IHC (Figures 3A and 3B) were
used to verify expected patterns of melanocyte growth and
nevus formation at each time point. BrafV600E melanocytes
weremuchmore abundant than control melanocytes, again con-
firming the proliferative effect of this genetic change (Figures
S3A and S3B). PCR was used to confirm recombination of Braf
in GFP+, but not GFP cells after the sort (Figure S3C).
Gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) was used to compare gene expression between prearrest
melanocytes, growth-arrested melanocytes, and Cdkn2a/Braf
melanomas. GSEA revealed that mTOR signaling was the most
differentially regulated pathway between prearrest and growth-
arrested melanocytes, with it being downregulated in growth-ar-
rested cells (Figure 3C and Table S1). Comparison ofmelanomas
to growth-arrested nevi revealed that reactivation of IGF1R/
mTORwas associated with progression to melanoma (Figure 3C
and Table S1). Ribosome synthesis, RNA polymerase produc-
tion, and protein translation were the most upregulated pro-
cesses associated with transition to melanoma (Figure 3C and
Table S1). These processes are regulated more directly by
mTORC1 than mTORC2 (Cantor and Sabatini, 2012; Chan
et al., 2011) and suggested that mTORC1 might have a central
role in growth arrest.
Figure 3. Melanocytic Nevi and Melanomas Differ in mTORC1 Pathway Activation Status
(A) Fluorescent stereomicroscopy of iDCT-GFP melanocytes in growth-arrested nevi (Cdkn2a/Braf) and control hair follicle melanocytes (Cdkn2a only); scale
bars, white, 1.2 mm; and yellow, 150 mm.
(B) GFP IHC of flank skin from Cdkn2a/Braf (BR) and Cdkn2a (WT) mice. Top: prearrest melanocytes are shown before (black arrowhead) and after (white
arrowhead) escape from the hair follicle, and in their normal anatomic location within the follicle (yellow arrowhead). Bottom: nevus melanocytes after growth
arrest; scale bars, black, 15 mm; red, 5 mm; white, 75 mm; and yellow, 20 mm.
(C) GSEA results comparing expression data from uncultured prearrest melanocytes, growth-arrested nevus melanocytes, and melanoma cells in the Cdkn2a/
Braf model.
See also Figure S3 and Table S1.
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mTORC1 Regulates BrafV600E-Induced Growth ArrestPten loss, through activation of PI3K/Akt signaling, is known
to release BrafV600E mutant melanocytes from OIS in vivo
(Dankort et al., 2009; Vredeveld et al., 2012). To understand dif-
ferences and similarities between Pten/Braf and Cdkn2a/Brafmelanomas at the signaling level, reverse-phase protein anal-
ysis (RPPA) was performed on these tumors. RPPA showed
activation of PI3K/Akt signaling and both mTORC1 and
mTORC2 as shared features of these two tumor types. AlthoughCancer Cell 27, 41–56, January 12, 2015 ª2015 Elsevier Inc. 45
Figure 4. Melanocytic Nevi and Melanomas Differ in MAPK/Erk, PI3K/Akt, and mTORC1 Activation Status
(A) IHC of flank skin from Cdkn2a/Braf mice at various time points. Arrowheads indicate melanocytes; scale bars, black, 20 mm; and red, 10 mm.
(B) Semiquantitative analysis of IHC data from (A); P, pregrowth arrest; G, growth arrested; and M, melanoma. *p < 0.05. Error bars represent SEM.
(C) IHC of flank skin from Cdkn2a/Braf mice at various time points. Arrowheads indicate melanocytes; scale bars, black, 20 mm; and red, 10 mm.
See also Figure S4.
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mTORC1 Regulates BrafV600E-Induced Growth Arrestmany downstream mediators of PI3K/Akt signaling were acti-
vated in Cdkn2a/Braf melanomas (data not shown), mTORC1
showed particularly high levels of activation (Figure S4A). Levels
of mTORC1 substrates, such as S6k and 4E-bp1, were often
even higher in Cdkn2a/Braf tumors than in Pten/Braf tumors,
which are known to have high levels of mTORC1 activity (Dan-
kort et al., 2009). These trends were confirmed with western
blots (Figure S4B). mTORC2 appeared to be activated at similar
levels in both tumor genotypes (Figure S4B). These analyses
combined with the GSEA data suggested that reactivation of
mTORC1 in growth-arrested Cdkn2a/Braf nevi might drive pro-
gression to melanoma.
Notably, activation of PI3K/Akt/mTOR signaling in Cdkn2a/
Braf melanomas occurred even in the presence of Pten protein
expression (Figure S4B). However, sequencing of the phospha-
tase domain-encoding region of Pten from ten Cdkn2a/Braf
tumors did not reveal any mutations (data not shown).
To compare levels of mTORC1 activation at the protein level
in tissue at various stages of melanomagenesis, IHC was per-
formed on skin from Cdkn2a/Braf mice at pre- and post-
growth-arrest time points and after progression to melanoma.
Levels of PI3K/Akt and MAPK/Erk were also examined. Prearr-
est melanocytes showed transient activation of MAPK/Erk
(p-Erk), mTORC1 (p-S6), and mTORC2 (p-AktS473); however,
activity of these pathways was lost in growth-arrested lesions
(Figures 4A and 4B). These results are consistent with results
from previous in vitro work (Courtois-Cox et al., 2006). As pre-46 Cancer Cell 27, 41–56, January 12, 2015 ª2015 Elsevier Inc.dicted by GSEA, progression to melanoma was associated with
hyperactivation mTORC1 signaling, in addition to mTORC2/Akt
and MAPK/Erk (Figures 4A and 4B). Cdkn2a/Braf nevi also
showed strong nuclear staining of other CKIs, such as p21
and p27, which were often lost or mislocalized to the cytoplasm
in tumors (Figures 4C and S4C). mTORC1 inhibits autophagy,
which has been postulated to play a role in OIS (Narita et al.,
2011; Young et al., 2009); but, analysis of Cdkn2a/Braf nevi
and melanomas for an autophagy marker (LC3B) suggested
limited activation of this process, with only small focal areas
of melanomas occasionally showing weak staining (Figure S4D).
However, without additional analyses, a role for autophagy
cannot be completely ruled out. Staining for a marker of endo-
plasmic reticulum stress (BiP) was also unrevealing (data not
shown).
We also tested the effect of mTORC1 inhibition on the progres-
sion of nevi to melanoma in the Cdkn2a/Braf model by treating
mice bearing growth-arrested nevi with metformin (an indirect
mTORC1 inhibitor that acts through the Lkb1/AMPK pathway)
or rapamycin (a direct mTORC1 inhibitor). Treatment with either
compound significantly delayed the progression of nevi to
melanoma and slowed the growth of melanomas to 1 cm in
size (Figures S4E–S4H).
Based on these analyses collectively, we hypothesized that
constitutively activemTORC1 signaling inBrafV600Emelanocytes
might be sufficient to bypass OIS and drive progression to
melanoma.
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mTORC1 Regulates BrafV600E-Induced Growth ArrestLkb1 Inactivation Abrogates BrafV600E-Induced Growth
Arrest but Does Not Lead to Melanoma Formation
mTORC1 is a central integration point that couples cellular en-
ergy status, amino acid levels, and upstream signaling changes
to control cellular growth and proliferation (Cantor and Sabatini,
2012). Regulatory inputs to mTORC1 at the signaling level
include the PI3K/Akt and Lkb1/AMPK pathways. While PI3K/Akt
activates mTORC1, the Lkb1/AMPK pathway inhibits mTORC1
under conditions of metabolic stress. Notably, STK11, which
encodes Lkb1, is mutated in approximately 10% of melanomas
(Forbes et al., 2008) and Lkb1 inactivation results in constitutive
mTORC1 activity (Cantor and Sabatini, 2012). Further, mTORC1
has been found to be almost universally activated in melanoma
(Karbowniczek et al., 2008) and Lkb1 inactivation previously
has been shown to cooperate with activated Kras to induce
melanoma in mice (Liu et al., 2012b), suggesting that Lkb1
loss, by providing a means by which to activate only mTORC1
(and not mTORC2), would result in bypass of BrafV600E-induced
OIS and lead to melanoma formation.
To test the effects of Lkb1 loss in BrafV600Emelanocytes, mice
carrying an Lkb1lox allele (Bardeesy et al., 2002) were mated to
TC;BrafCA mice. Inactivation of Lkb1 during Braf-induced prolif-
eration indeed abrogated detectable growth arrest. Rather than
forming discrete growth-arrested lesions, melanocytic prolifera-
tions in Lkb1/Braf mice grew to confluence (Figures 5A–5C).
Lkb1/Braf mice also exhibited significantly darkened hairs (Fig-
ure S5A), a change accompanied by increased melanin on histo-
logic analysis (Figure S5B). Given the striking alteration to nevus
phenotype, it was surprising that Lkb1/Brafmice did not develop
frank melanomas. Even at >1 year of age, mice did not exhibit
palpable masses or require euthanasia, as in other melanoma
models, including the previously published Lkb1/Kras model
(Liu et al., 2012b).
Lkb1/Braf lesions stained positively for S100 (Figure S5C).
Lesions showed levels of mTORC1 (p-4E-bp1 and p-S6) and
MAPK/Erk (p-Erk) activation between those of growth-arrested
nevi and melanomas from the Cdkn2a/Braf model (Figures 5D
and S5D). Ki67 indices and mitotic figure counts were also inter-
mediate even at later time points (Figures S5E and S5F).
Additionally, the skin of these mice showed a progressive accu-
mulation of melanocytes with advancing age, also consistent
with slow proliferation over time (Figure 5E). Pyknotic nuclei
(apoptotic cells) were not visible by histologic analysis (Figures
S5G and S5H), suggesting these melanocytes did not undergo
a significant degree of apoptosis.
mTORC2-mediated phosphorylation of Akt (p-S473) was not
detectable in Lkb1/Brafmelanocytic lesions (Figure 5F). Nuclear
p27 and p21 staining were present in Lkb1/Braf lesions, also at
intermediate levels (Figures S4C and S5D). Lkb1/Braf lesions
retained strong p19Arf staining with nucleolar accentuation (Fig-
ure S5I), suggesting the Cdkn2a locus remained intact.
18F-fluorodeoxyglucose positron emission tomography (FDG-
PET) is a commonly used imaging modality that relies on
increased uptake of a radioactive glucose analog by cancer
cells. FDG-PET positivity is a feature of many malignant tumors
including invasivemelanoma. As an alternativemeans of charac-
terizing Lkb1/Braf lesions, we measured glucose uptake in these
lesions. 2-NBDG, a fluorescent glucose analog, was adminis-
tered tomicewith Lkb1/Braf lesions to compare levels of glucoseuptake in growth-arrested nevi and melanomas from the
Cdkn2a/Braf model. Cdkn2a/Braf tumors showed avid 2-NBDG
uptake but growth-arrested nevi did not, even at themicroscopic
level (Figure 5G). In Lkb1/Braf lesions, 2-NBDG uptake was also
not detectable (Figure 5G), providing additional evidence that
these lesions were not fully malignant. Strikingly, 2-NBDG, which
also highlights vasculature shortly after intravenous administra-
tion, showed an extensive vascular network in the skin of
Lkb1/Braf mice that was not present in Cdkn2a/Braf mice with
growth-arrested melanocytic nevi (Figure 5G). Taken together,
these data demonstrate that Lkb1/Braf lesions, while having
bypassed OIS, are not frankly malignant, suggesting additional
factors are required for full progression to malignancy.
In addition to regulating mTORC1 activity, Lkb1 is also known
to affect cellular differentiation, cell polarity, and metastasis
(Herrmann et al., 2011). The tuberous sclerosis complex (TSC)
composed of TSC1 and TSC2 is a more direct and specific regu-
lator of mTORC1. TSC integrates inputs from PI3K/Akt, Lkb1/
AMPK, and MAPK/Erk pathways to regulate mTORC1 activity
(Cantor and Sabatini, 2012). To address potential mTORC1-in-
dependent effects of Lkb1 inactivation, TSC was inactivated
in BrafV600E melanocytes by mating TC;BrafCA mice to mice
with a conditionally inactivatable Tsc1 allele (Kwiatkowski
et al., 2002). Tsc1 inactivation resulted in a phenotype similar
to Lkb1 inactivation. Impaired growth arrest was observed with
melanocytic lesions often reaching confluence (Figures 5E, 5H,
and S5J).
Lkb1/Braf mice were also treated with rapamycin to address
whether inhibition of mTORC1 could restore Braf-induced OIS.
Lkb1/Brafmice treated with rapamycin had less confluent mela-
nocytic lesions than vehicle-treatedmice at 2months of age (Fig-
ure S5K). Together, these data suggest that the major effect of
Lkb1 or Tsc1 loss on BrafV600E melanocytes is through constitu-
tive activation of mTORC1.
Cdkn2a Loss Leads to Progression of Lkb1/Braf Lesions
to Melanoma
Lkb1 loss in BrafV600E melanocytes abrogated OIS, but was
insufficient for full malignant transformation. Next, we tested
the effects of Cdkn2a loss in the Lkb1/Braf model. As expected,
Cdkn2a/Lkb1/Braf melanocytes did not exhibit growth arrest;
however, surprisingly, melanoma occurred seemingly universally
throughout the skin of Cdkn2a/Lkb1/Braf mice with minimal
latency. Histologic analysis of the skin showed confluent trans-
formation of these benign melanocytic lesions to melanoma
(Figures 6A and 6B). In addition to diffuse tumor growth
throughout the skin, an average of 25 palpable tumor masses
was present per mouse (Figure S6A). In striking contrast to
Lkb1/Braf lesions, 2-NBDG was taken up diffusely both
throughout histologically involved skin as well as the palpable
masses inCdkn2a/Lkb1/Brafmice (Figures 5G and 6C). Notably,
inactivation of only one copy of Lkb1 was sufficient to rapidly
inducemelanoma in combination withCdkn2a loss andBraf acti-
vation (Figures 6A, S6A, and S6B) and result in activation of
mTORC1 in tumors (Figure S6C). mTORC1 activation with loss
of only one copy of Lkb1 has been reported previously (Morton
et al., 2010), though the explanation for this is not yet clear.
Levels of mTORC1 activity were similar to levels in Cdkn2a/
Braf melanomas that had stochastically activated this pathwayCancer Cell 27, 41–56, January 12, 2015 ª2015 Elsevier Inc. 47
Figure 5. Lkb1 Inactivation Abrogates BrafV600E-Induced Growth Arrest but Does Not Lead to Melanoma Formation
(A and B) H&E-stained flank skin from perinatally treated Lkb1/Braf (A) and Braf (B) mice. Arrowheads indicate nevi; scale bar, 200 mm.
(C) Stereomicroscopy of the epidermal surface of flank skin from a 9-month-old Lkb1/Brafmouse with the hair removed (top). Dark black dots (e.g., red circle) are
very slowly growing lesions that are depicted histologically in cross-section (red box, bottom). Confluent areas of melanocytes in the dermis can be seen in the
diffuse light-gray-appearing areas (P, top) and correspond to areas of confluent dermal melanocytes that can be seen histologically (white arrowhead); scale bars,
white, 1 mm; and red, 75 mm.
(D) Semiquantitative analysis of IHC staining data from Figures 4A, 4B, and 5F. Nevi and melanoma (Mel) data are from Cdkn2a/Braf mice as in Figure 4C. NS
indicates no statistically significant difference. Error bars represent SEM.
(E) Quantification of melanocytes in skin. Error bars represent SEM.
(F) p-Akt (S473) staining of melanocytic lesions in Lkb1/Braf and Cdkn2a/Lkb1/Braf mice; scale bar, 10 mm.
(legend continued on next page)
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Figure 6. Cdkn2a Loss Leads to Progression of Lkb1/Braf Lesions to Melanoma
(A) Kaplan-Meier survival analysis of mice treated perinatally with 4-HT.
(B) H&E-stained flank skin from Cdkn2a/Braf/Lkb1 mice at different time points. Arrowhead indicates the same anatomic landmark (panniculus carnosus) for
reference; scale bar, 200 mm.
(C) 2-NBDG uptake Cdkn2a/Braf and Cdkn2a/Lkb1/Braf mice.
(D) Stereomicroscopy (left and middle) and H&E staining (right) showing metastases in liver (left and top right) and spleen (middle and bottom right) from Cdkn2a/
Lkb1/Braf mice; scale bars, black, 250 mm; and white, 500 mm.
See also Figure S6.
Cancer Cell
mTORC1 Regulates BrafV600E-Induced Growth Arrest(Figure S6C). Large metastases to the liver and spleen were
present in a subset of mice from this cohort (Figure 6D).
Activation of the mTORC2/Akt Pathway Is Associated
with Full Progression to Malignancy
Pten/Braf tumors also showed avid 2-NBDG uptake (data not
shown), suggesting that other downstream mediators of acti-
vated PI3K/Akt in addition tomTORC1 are required for full malig-
nant transformation. mTORC2, which was found to be activated
in Cdkn2a/Braf melanomas, also was activated with Pten loss.
mTORC2 has been shown to be required for full activation of
Akt, and is required for Pten loss-induced malignancy in the
prostate (Guertin et al., 2009). Notably, RICTOR, which encodes
the mTORC2 component Rictor, is amplified in a subset of
human melanomas (Krauthammer et al., 2012). Interestingly,
in contrast to Lkb1/Braf melanomas, Cdkn2a/Lkb1/Braf mela-(G) 2-NBDG uptake in Cdkn2a/Braf nevi and melanomas, Lkb1/Braf lesions, and
scale bar, 5 mm.
(H) Stereomicroscopy (top, viewed from the dermal side) and H&E staining (botto
125 mm.
See also Figure S5.nomas reproducibly exhibited diffuse p-Akt (S473) staining
consistent with robust mTORC2 activation (Figure 5F). GSEA
comparing Lkb1/Braf lesions with Cdkn2a/Lkb1/Braf mela-
nomas showed that Akt signaling was one of the most differen-
tially downregulated pathways in Lkb1/Braf lesions (Table S2),
again suggesting that full activation of Akt via activation of
mTORC2 is critical for inducing a fully malignant phenotype
characterized by diffuse 2-NBDG uptake and rapid, infiltrative
growth.
Full activation of Akt downstream of PI3K is mediated by both
PDK1- (p-T308) and mTORC2- (p-S473) mediated phosphoryla-
tion. p-Akt (T308) phosphorylation is thought to be essential
for downstream activation of mTORC1, whereas p-Akt (S473)
is thought to be closely associated with negative downstream
regulation of FoxO tumor suppressors (Jacinto et al., 2006).
As activation of both mTORC1 and mTORC2 appeared to beCdkn2a/Lkb1/Braf melanomas in albino mice, which lack pigment production;
m) of flank skin from a Tsc1/Brafmouse; scale bars, white, 1.2 mm; and black,
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Figure 7. Activation of the mTORC2/Akt Pathway Is Associated with Full Progression to Malignancy
(A) FoxO1IHC of a nevus and a melanoma from a Cdkn2a/Braf mouse and FoxO1 and p-S6 IHC of a human nevus and melanoma; scale bar, 10 mm.
(B) Proliferation assays (left), photomicrograph (top right, scale 10 mm), and western blot of cell lysates (bottom right) of the 2901 Pten/Brafmouse melanoma cell
line treated with Rictor or control shRNAs. *p < 0.05. Error bars represent SE of difference; RLU, relative luminescence units.
(C) Comparison of various phosphorylated proteins in TCGA melanomas with and without p16Ink4a upregulation (top) and with or without CDKN2A copy number
losses (bottom). Akt substrates include TSC and GSK3. NRDG1 is downstream of mTORC2 substrate SGK1. NC indicates no change.
(D) Fold upregulation of miR-99/100 after BrafV600E mutation (left) and fold increase in miR-99/100 levels in growth-arrested nevi relative to melanomas in the
Cdkn2a/Braf model (right). Error bars represent SEM.
(E) Proliferation assays in the 2697 Pten/Braf mouse melanoma cell line grown in low-serum (1% fetal bovine serum) conditions and treated with miR-99/100
mimics, control mimics, or control mimics and rapamycin. Error bars represent SE of difference.
(legend continued on next page)
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mTORC1 Regulates BrafV600E-Induced Growth Arrestrequired for full progression tomalignancy, we decided to further
evaluate the status of the mTORC2/Akt/FoxO pathway in nevi
and melanomas.
FoxO proteins are tumor suppressors that regulate cellular
growth, metabolism, cell cycle progression, apoptosis, and
glycolysis (Monsalve and Olmos, 2011). Activated Akt regulates
FoxO activity through phosphorylation, which results in cyto-
plasmic sequestration and inhibition of tumor suppressive func-
tions (Monsalve and Olmos, 2011). FoxO proteins previously
have been shown to be upregulated in cultured fibroblasts in
response to RAS-induced OIS (Courtois-Cox et al., 2006; Young
et al., 2009); however, their status has not been carefully docu-
mented in melanocytic lesions.
The status of FoxO proteins in Cdkn2a/Braf nevi and mela-
nomas was characterized using IHC. Nevi showed strong nu-
clear FoxO1 staining, while melanomas generally showed only
weak cytoplasmic FoxO1 positivity (Figure 7A). Lkb1/Braf lesions
also showed strong FoxO1 staining (Figure S7A), consistent with
the observation that mTORC2-mediated phosphorylation of Akt
(S473) does not occur in these lesions. It has been observed pre-
viously that inhibition of mTORC1 by FoxO proteins prevents
mTORC1-mediated tumorigenesis (Gan et al., 2010), consistent
with the incompletely malignant phenotype of Lkb1/Braf lesions.
To determine if similar patterns were present in human lesions,
a series of human nevi and melanomas were stained for p-S6
and FoxO1 to assess the activation status of mTORC1 and
mTORC2. These samples included several BRAFV600E mutant
melanomas with loss of p16Ink4a expression (Table S3). Promi-
nent nuclear FoxO1 staining was present in nearly all nevi, with
either no or weak (mostly cytoplasmic) staining in most mela-
nomas (Figures 7A and S7B), consistent with mTORC2/Akt acti-
vation. These data are consistent with previous studies in human
melanoma specimens showing increased p-Akt (S473) staining
in melanomas relative to benign nevi (Kantrow et al., 2007).
p-S6 staining was generally very strong in melanomas, but
weak or absent in nevi (Figures 7A and S7C). Together, these
results support the hypothesis that both mTORC1 and mTORC2
activation are associated with a fully malignant phenotype in
BrafV600E lesions.
To test the requirement for mTORC2 signaling in Braf-driven
melanomas with constitutive PI3K/Akt signaling, Pten/Braf mu-
rine melanoma cell lines were treated with small hairpin RNAs
(shRNAs) targeting Rictor. Rictor knockdown significantly in-
hibited the growth of these two cell lines (Figures 7B,S7D, and
S7E) and decreased phosphorylation of Akt (S473) (Figure 7B).
Knockdown of Sin1, another mTORC2 component, also signifi-
cantly reduced proliferation (Figures S7F and S7G) and
decreased mTORC2/Akt signaling in Pten/Braf melanoma cell
lines (Figure S7H).
As Cdkn2a loss in Lkb1/Braf lesions resulted in robust and
reproducible mTORC2 activation and full progression to malig-
nancy, we explored the relationship between Cdkn2a loss and(F) Western blot of cell lysates from 2697 cells treated with miR-100 mimic or co
(G) Western blot analysis using cell lysates from uncultured Pten/Braf and Cdkn2
(H) Western blot of cell lysates from Pten/Brafmurine cell lines 2697 and 2901 and
or control.
(I) IGF1 and IGF2 mRNA levels in Cdkn2a/Braf nevi and melanomas (Mel). Error b
See also Figure S7 and Tables S2, S3, and S4.activation of mTORC2/Akt in 43 human melanoma cell lines us-
ing RPPA. In these melanoma cell lines, loss of p16Ink4a expres-
sion was associated with increased Akt phosphorylation (S473
and T308), but not total Akt protein (Figures S7I and S7J). A
similar analysis was performed in a larger data set of 204 human
melanomas from The Cancer Genome Atlas (TCGA) database. In
these melanomas, increased p16Ink4a levels were significantly
associated with decreased p-Akt-S473, p-Akt-T308, and p-
NRDG1-T346 (Figure 7C). Decreased Akt activity in the presence
of increased p16Ink4a was demonstrated by lower levels of Akt
substrate phosphorylation (p-TSC2-T1462 and p-GSK3b-S9/
S21) (Figure 7C). Additionally, CDKN2A copy number reductions
were associated with increased phosphorylation of themTORC2
component Rictor (Figure 7C), a change associated with activa-
tion of upstream PI3K signaling (Boulbes et al., 2010).
miR-99/100 Family Dysregulation Characterizes the
Nevus to Melanoma Transition
To better understand themechanism bywhich stochastic activa-
tion of mTOR signaling might occur inBrafV600Emelanocytes, we
performed additional GSEA using an algorithm that predicts
potentially dysregulated microRNAs (miRNAs). Growth-arrested
nevi and melanomas in the Cdkn2a/Brafmodel were compared.
GSEA data were compared with data from previous global
miRNA analyses in melanocytic lesions to identify miRNAs that
were both upregulated in nevi and appeared to be associated
with activation of MAPK/Erk signaling (Couts et al., 2013; Liu
et al., 2012a; Ren et al., 2012; Xu et al., 2012). ThemiR-100 family
(consisting of miR-99a, 99b, and 100) was the only group of
miRNAs that met these criteria across all data sets (Table S4).
Notably, miR-99/100 are most well known for their ability to
downregulate mTOR signaling (Gebeshuber and Martinez,
2013). Accordingly, the hypothesis that Braf mutation, by acti-
vating miR-99/100 signaling, might provide a feedback mecha-
nism to downregulate mTOR signaling was explored. This
hypothesis also predicts that downregulation of miR-99/100
(and reactivation of mTOR) would be associated with progres-
sion to melanoma.
Introduction of BrafV600E in cultured murine melanocytes
derived from TC;BrafCA/WT mice resulted in upregulation of
miR-99/100 (Figure 7D). To functionally evaluate the effects of
miR-99/100 in the melanocytic lineage, BRAFV600E human and
mouse melanoma cell lines were treated with synthetic mimics
of miR-99/100. Mimic treatment resulted in reduced proliferation
to a degree similar to that of the mTORC1 inhibitor rapamycin
(Figures 7E, S7K, and S7L), as well as inhibition of mTORC1 acti-
vation (Figure 7F). Quantitative RT-PCR of lesions from Cdkn2a/
Braf mice showed that the miR-99/100 level was significantly
higher in nevi than in melanoma (Figure 7D). As IGF1R/mTOR
signaling was found to be upregulated in Cdkn2a/Braf mela-
nomas relative to nevi in initial GSEA analyses, combined with
the observation that miR-99/100 has been shown to directlyntrol.
a/Braf melanomas.
the human BRAFV600Emelanoma cell line 501MEL treated with miR-100 mimic
ars represent SEM.
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Figure 8. Summary of BrafV600E-Based Mouse Models
(A) Prior to growth arrest, Cdkn2a/Braf melanocytes exhibit transient MAPK/Erk, mTORC1, and mTORC2/Akt activation.
(B) After growth arrest, Cdkn2a/Braf nevus melanocytes do not exhibit detectable levels of MAPK/Erk, mTORC1, and mTORC2 activation, with mTORC1 and
mTORC2 suppression regulated by upregulation of miR-99/100.
(C) Transition to melanoma in theCdkn2a/Brafmodel is associated with hyperactivation of MAPK/Erk, mTORC1, andmTORC2 and is associated with decreased
miR-99/100 and increased IGF1-mediated activation of IGF1R signaling.
(D) Lkb1/Braf lesions are associated with basal MAPK/Erk and mTORC1 pathway activation, but not mTORC2/Akt activation. Lkb1/Braf melanocytic lesions
neovascularize the microenvironment, but do not exhibit rapid glucose uptake or rapid, infiltrative growth.
(legend continued on next page)
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of IGF1R in the Cdkn2a/Braf model was examined. Cdkn2a/
Braf melanomas showed strong upregulation and activation
(phosphorylation) of IGF1R (Figure 7G) relative to Pten/Braf
melanomas.
Treatment of murine melanoma cell lines with miR-99/100
mimics resulted in downregulation of IGF1R (Figure 7H) in addi-
tion to the inhibition of proliferation. These observations are
consistent with observations from human melanocytic lesions,
where progression from nevi to melanoma in tissue sections
was associated with increased expression of IGF1R (Kanter-
Lewensohn et al., 2000). The expression of IGF1 was higher in
Cdkn2a/Braf melanomas than in nevi (Figure 7I), suggesting a
means by which IGF1R becomes activated once it is overex-
pressed. In summary, these data suggest that miR-99/100
expression in melanocytic nevi help to prevent progression to
melanoma by inhibiting IGF1R (and downstream PI3K/Akt) and
mTOR, and, in doing so, inhibiting activation of mTORC1 and
mTORC2 signaling.
DISCUSSION
Our findings together can be incorporated into a model of Braf-
induced melanocytic proliferation (Figure 8). CDKN2A locus
disruption, which affects p16Ink4a and/or p14Arf, is common in
both sporadic and familial melanomas (Tsao et al., 2012).
Cdkn2a/Braf mice form slightly larger nevi than mice with Braf
activation alone, but these lesions still exhibit stable growth
arrest and rarely progress to melanoma, suggesting that loss
of Cdkn2a is insufficient to release melanocytes from OIS,
consistent with previous reports (Dhomen et al., 2009; Hafer-
kamp et al., 2009). However, Cdkn2a loss primes a subset of
growth-arrested, BrafV600E nevi for later stochastic progression
to melanoma, which appears to occur through activation of
Akt/mTORC2 and mTORC1 signaling.
miR-99/100 upregulation (and consequent mTOR and IGF1R
downregulation) after Braf activation appears to be an important
early event enforcing growth arrest after an initial proliferative
burst. This effect is consistent with the previously documented
inhibitory function of miR-99/100 toward mTOR and IGF1R/Akt
(Gebeshuber and Martinez, 2013; Jin et al., 2013). Inhibition of
mTOR and IGF1R/Akt signaling by miR-99/100 after Braf activa-
tion likely acts in concert with other previously defined feedback
loops regulating MAPK/Erk and PI3K/Akt signaling pathways
(Dent, 2014). Stochastic progression to melanoma in the
Cdkn2a/Braf model is associated with loss of robust miR-99/
100 expression and activation of mTORC1 and IGF1R/mTORC2,
which help drive melanoma formation in combination with acti-
vated MAPK/Erk. These patterns are consistent with studies
from human melanocytic lesions showing that (1) miR-99/100
are present at higher levels in melanocytic nevi relative to mela-
nomas (Liu et al., 2012a; Xu et al., 2012), and (2) increased IGF1R
is associated with progression of nevi to melanoma in tissue
sections (Kanter-Lewensohn et al., 2000).(E and F) Cdkn2a/Lkb1/Braf (E) and Pten/Braf (F) melanomas are associate
malignant phenotype. In Cdkn2a/Lkb1/Braf melanomas, activation of MAPK/
Lkb1, and Cdkn2a, respectively. These melanomas show all features of m
glucose uptake.The signaling pathways that cooperate with MAPK/Erk activa-
tion in BRAFV600E melanoma are of great interest. Pten loss has
been shown to abrogate Braf-induced OIS and lead to rapid
melanoma formation in vivo (Dankort et al., 2009; Vredeveld
et al., 2012). In the Pten/Braf model, concomitant activation of
mTORC1 and mTORC2/Akt was observed; however, whether
activation of either mTOR complex alone was sufficient for pro-
gression to melanoma in BrafV600E melanocytes was previously
unknown.
Lkb1 loss has been shown to cooperate with Kras activation to
induce metastatic melanoma in mice (Liu et al., 2012b), suggest-
ing a similar effect might be observed in combination with Braf
activation. Interestingly, BRAFV600E has been shown to inhibit
Lkb1 function (Esteve-Puig et al., 2009; Zheng et al., 2009), lead-
ing to the additional prediction that genetic inactivation of Lkb1
in the context of Braf activation might have had a relatively
redundant effect. In this study, we showed that, in BrafV600E
melanocytes, although Lkb1 loss leads to bypass of OIS and
continuous, low-grade proliferation over time, full progression
to malignancy does not occur. These data suggest that the ef-
fects of Lkb1 loss in Ras mutant and Braf mutant melanocytes
are not equivalent, withmTORC1 activation having different con-
sequences in these two contexts. In the Lkb1/Braf model, it is
possible that tumor formation is prevented by activation of
known feedback loops downstream of mTORC1, which inhibit
growth factor/PI3K/Akt signaling andmTORC2 activation (Beau-
champ and Platanias, 2013). Ras, which signals through MAPK/
Erk, but also to some degree through PI3K/Akt, may be less
susceptible to such feedback loops, possibly explaining the
observation that Lkb1 loss drives malignant progression in
Kras mutant melanocytes.
Inactivation ofCdkn2a in the Lkb1/Brafmodel results in robust
mTORC2/Akt activation and transformation of benign melano-
cytic lesions into rapidly progressive melanomas, similar to
that observed in the Pten/Brafmodel. Analysis of signaling in hu-
man melanomas also showed that CDKN2A loss is associated
with activation of mTORC2/Akt signaling. These observations
together suggest that p16Ink4a and p19Arf may play roles broader
than their canonical functions in RB signaling/G1 restriction point
and p53 signaling pathways, respectively. For example, p16Ink4a
has a central role in cellular homeostasis and aging (LaPak and
Burd, 2014), while p19Arf has been shown to play important roles
in metabolism and nucleolar biology (Maggi et al., 2014). The ef-
fect of Lkb1 loss on liver and spleen metastasis in the Cdkn2a/
Lkb1/Braf model is notable and is consistent with the metas-
tasis-restricting role previously attributed to Lkb1 by Liu et al.
(2012b). At this time, it is unclear whether the effects of Lkb1
loss on metastasis in the Cdkn2a/Lkb1/Brafmodel are mTORC1
dependent or occur through a mechanism similar to that
described previously.
More broadly, the Cdkn2a/Brafmodel suggests that OIS does
not unequivocally restrict melanoma formation in vivo, and that
under appropriate conditions OIS can be reversed. The Lkb1/
Braf model demonstrates that abrogation of OIS throughd with MAPK/Erk, mTORC1, and mTORC2 hyperactivation and a rapidly
Erk, mTORC1, and mTORC2/Akt are achieved through alterations to Braf,
alignancy: rapid, infiltrative growth; robust neovascularization; and rapid
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progression to malignancy; which also requires activation of
mTORC2/Akt. The natural history of melanocytic neoplasms in
humans is complex, with significant gray area between benign
and malignant lesions, which is further complicated by the fact
that lesion characteristics can evolve over time as additional ge-
netic and epigenetic alterations are acquired. The Cdkn2a/Braf
and Lkb1/Braf models reflect the complexity and clinical vari-
ability observed in human melanocytic neoplasms and under-
score the importance of additional changes in determining
the outcome of BRAFV600E mutation. Improved understanding
of the basic requirements for melanocytic malignancy down-
stream of activated MAPK/Erk, PI3K/Akt, and both mTORC1
and mTORC2 will inform diagnosis and targeted treatment of
melanoma.
EXPERIMENTAL PROCEDURES
Mouse Strains
The Tyr-CreERT2,BrafCA,Cdkn2alox,Tr p53lox, Lkb1lox, Tsc1lox, and iGFP alleles
have been described previously and were genotyped and assayed for recom-
bination using PCR. These alleles are described in the Supplemental Experi-
mental Procedures. All mice were maintained on a mixed C57BL/6, FVB,
and 129 background. All experiments involving animals were reviewed and
approved by the Yale Institutional Animal Care and Use Committee.
Nevi, IHC, and Western Blotting
Melanocytic nevi in Cdkn2a/Braf mice were defined as clinically growth ar-
rested pigmented lesions in flank skin. Melanomas were defined as palpable
skin tumors. Histological criteria were also used to distinguish between nevi
and melanoma. IHC was performed on formalin-fixed paraffin-embedded
skin and tumor sections. Western blotting was performed using standard
methods and cell lysates were prepared from macrodissected tumor sam-
ples or cultured melanoma cell lines. The archival human samples that
were used in the study were collected for other purposes, deidentified,
and determined to meet criteria for Exemption 4 by the Yale Institutional
Review Board.
FACS Isolation of Melanocytes, RNA Purification, and Microarray
Analysis
Mouse skin was dissociated with collagenase and stained for FACS analysis
by standard methods. FACS purification was performed using a Becton Dick-
inson FACS Aria, and RNA was purified using the QIAGEN RNeasy micro kit.
Amplification, cDNA synthesis, and microarray analysis were carried out at
the University of Vermont/Vermont Cancer Center microarray core facility.
mMiRNA mimic and in vitro knockdown experiments are described in the
Supplemental Experimental Procedures.
Statistical Analyses
Kaplan-Meier survival curves were compiled using GraphPad Prism statistical
analysis software. Significance was assessed using the log rank (Mantel-Cox)
test. Other statistical analyses also were conducted in Prism. GSEA was
performed using publicly available software provided by the Broad Institute.
ACCESSION NUMBERS
Microarray data sets were deposited in the National Center for Biotechnology
Information’s Gene Expression Omnibus database with accession number
GSE61750.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
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